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Non-speciﬁc bronchial hyper-responsiveness
in children with allergic rhinitis: Relationship
with the atopic status
Bronchial hyper-responsiveness (BHR) is consid-
ered a distinctive functional characteristic of
asthma and it is associated with an increased risk
for developing bronchial asthma both in children
and adults (1). BHR can be detected frequently in
subjects suﬀering from allergic rhinitis alone, thus
suggesting that a common pathogenic mechanism
operates in the lower airways in allergic rhinitis
and asthma. The methacholine (Mch) challenge is
the most commonly used and better standardized
test for quantifying BHR. Also the spontaneous
changes in airway patency, measured by assessing
the variability of daily peak expiratory ﬂow
(PEFv), is a reliable indirect marker of BHR
(2). An increased prevalence of BHR has been
demonstrated in children in a general population
setting (3), as well as in adult allergic subjects
with rhinitis symptoms and no evidence of
asthma, related to lower respiratory tract involve-
ment (4). Moreover, non-asthmatic children with
allergic rhinitis are most likely to have BHR (5).
Nevertheless, at the present, the clinical signiﬁ-
cance of asymptomatic BHR remains to be fully
understood (6). Many factors (e.g., atopic status,
family history, sensitization, age at onset of
disease, etc.) have been reported to aﬀect at
variable extent the relationships among BHR,
rhinitis, and asthma, but a comprehensive eval-
uation of these factors together in a carefully
selected population still lacks.
The aim of the present study was to evalu-
ate the prevalence of BHR in a sample of
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An increased prevalence of bronchial hyper-responsiveness (BHR) has
been demonstrated in children from a general population, and in non-
asthmatic adults with allergic rhinitis. Thus, also children with allergic
rhinitis are expected to be at higher risk of BHR. We evaluated the
prevalence of BHR in a sample of non-asthmatic children with allergic
rhinitis by means of the methacholine (Mch) bronchial challenge, and
by monitorizing the airway patency using the daily peak expiratory ﬂow
variability (PEFv). Fifty-one children (ranged 6–15 years of age) with
allergic rhinitis, ascertained by skin prick test to inhalant allergens,
underwent a 14-day peak expiratory ﬂow monitoring, and a Mch
bronchial provocation challenge. Thirty healthy children matched for
age, and sex served as control group. Thirty-one children in the rhinitis
group (61%), and six (20%) in the control group were Mch+ (Mch
provocative dose causing a 20% fall of forced expiratory volume in 1 s
respect to baseline <2250 lg, equivalent to 11.50 lmol). In rhinitic
children the PEFv did not signiﬁcantly diﬀer between Mch+ and Mch)
subjects, but the total serum immunoglobulin E (IgE) were higher
among Mch+. The persistent form of rhinitis was signiﬁcantly associ-
ated to Mch positivity. Non-asthmatic children with allergic rhinitis
displayed a high prevalence of BHR. The BHR was signiﬁcantly asso-
ciated with persistent rhinitis and with higher total IgE levels. Never-
theless, the spontaneous changes in airway patency, as expressed by
PEFv, were within normal limits both in Mch+ and Mch) children.
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non-asthmatic children with allergic rhinitis, by
measuring the Mch reactivity and the daily
variability of PEF. A number of concomitant
demographic and clinical aspects, and their
relationship with BHR were evaluated as well.
Methods
Study design
The present study is a cross-sectional evaluation
of bronchial hyper-responsiveness in a group of
51 children with allergic rhinitis alone and in a
matched control group of 30 healthy non-allergic
children. All subjects were investigated for their
clinical history and underwent a careful diagnos-
tic evaluation including: skin prick test (SPT),
total serum immunoglobulin E (IgE) measure-
ment, pulmonary function testing, and Mch
bronchial challenge. All parents of the subjects
signed a written informed consent. The study was
approved by the inner Ethical Committee.
According to the Italian law, the respect of
individual privacy concerning clinical data was
granted.
Subjects and diagnosis
The two groups of children were selected from
consecutive outpatients attending the allergy unit
of a teaching hospital for the ﬁrst time. The
rhinitis group consisted of patients fulﬁlling the
following criteria:
(i) clinical diagnosis of rhinitis (7) based on the
clinical history of nasal blockage, sneezing,
itching, and discharge not because of com-
mon cold;
(ii) positive SPT for one or more inhalatory
allergens;
(iii) no ongoing pharmacologic treatment for
rhinitis on a regular basis or speciﬁc immu-
notherapy.
The subjects of the control group were seen as
well at the allergy unit, but for non-respiratory
symptoms (e.g., urticaria, drug intolerance): they
had negative SPT and negative clinical history for
rhinitis. None of the children of both groups had
a history of asthma symptoms, including diurnal
or nocturnal wheezing, recurrent dry cough,
shortness of breath, chest tightness or exercise-
related respiratory symptoms. All of them were
free from upper or lower respiratory tract infec-
tions in the 30 days preceding the study. The
treatment prescription, if any, for rhinitis was
postponed to the end of the study (14 days).
In the group of children with allergic rhinitis,
age of disease onset, disease duration, passive
smoke exposure, and family history were
assessed in detail. The familial atopic risk was
evaluated according to the criteria of Croner and
Kjellman (8). Allergic rhinitis was classiﬁed as
persistent (symptoms at least 4 days per week
and more than 4 weeks per year) or intermittent
(symptoms <4 days per week or <4 weeks per
year), according to the recent guidelines (9).
Skin prick test was carried out with a standard
panel of commercial extracts (Lofarma S.p.A,
Milan, Italy). The panel included: Dermatophag-
oides pteronyssinus, grass pollen, Parietaria juda-
ica, Phleum pratense, artemisia, olive, dog and
cat dander, alternaria, and Cladosporium plus a
positive (histamine 1%) and a negative (isotonic
saline) control. The response was measured after
15 min as the mean value of the major diameter
of the wheal and its orthogonal; a reaction of
5 mm or greater was considered positive (10).
Total serum IgE were determined in all subjects
by latex nephelometry (Behring Institute,
L’Aquila, Italy), log-transformed and expressed
as Z-scores (11) according to age groups 6–10
and 11–16 years. All the positive SPTs were
conﬁrmed by measuring speciﬁc IgE using the
FEIA-CAP System (Pharmacia, Upssala, Swe-
den) (12). Speciﬁc IgE were considered positive if
their concentration was 0.36 kU/l (CAP class I).
A peripheral eosinophil count was also per-
formed in allergic children.
Peak expiratory flow monitoring
All rhinitis subjects were instructed to use twice
daily (after awakening and at bedtime) a port-
able peak expiratory ﬂow rate meter (Mini
Wright Peak Flow Meter, Clement Clarke Ltd,
London, UK), performing forced expiratory
maneuvers in standing position starting from
vital capacity and selecting the best of three
consecutive measurements. All subjects recorded
on a diary card PEF measurements and any
respiratory symptom occurring over the 14 con-
secutive day period before Mch challenge. PEFv
was computed as 14-day mean of the daily
diﬀerences between the highest and lowest values
expressed as percent of the daily mean, according
to the formula (13):
PEFv ¼ 1
14

X14
1
MaxMin
X
where Max, Min and X are the daily maximum,
minimum, and mean values, respectively.
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Pulmonary function tests and methacholine challenge
Pulmonary function tests (PFT) were performed
in all subjects by a computerized water-sealed
spirometer (Biomedin, Padua, Italy). Baseline
forced vital capacity (FVC), forced expiratory
volume in 1 s (FEV1), and FEV1/FVC ratio,
were measured. Mch bronchial provocation test
was performed using an ampoule-dosimeter
(Mefar Elettromedicali, Brescia, Italy). An
inspiratory eﬀort for 0.5 s activated a solenoid
valve, delivering 5 ll of solution. Lyophilized
Mch chloride (Lofarma S.p.A) was reconstituted,
to obtain 0.2% and 1.0% concentrations. After
saline control, Mch was administered in double
increasing amounts: each subject inhaled one and
two breaths of 0.2% Mch solution (each breath
corresponding to 10 lg of Mch), followed by 1, 2,
4, 8, 16, and again 16 breaths of 1.0% solution
(each corresponding to 50 lg of Mch). FEV1 was
recorded about 2 min after each Mch dose (14).
All bronchial challenges were performed at the
same hour of the day under the same environ-
mental conditions. The Mch test was carried out
of the pollen season in those patients with
pollinosis. The cumulative administered dose of
Mch causing a reduction of 20% of the baseline
FEV1 (PD20) was computed by interpolating the
Mch cumulative doses immediately preceding
and following the 20% fall of FEV1. Subjects
showing a PD20 <2250 lg Mch (equivalent to
11.50 lmol Mch) were considered as responders
(Mch+), and the remaining were considered
non-responders (Mch)). Dose-response slopes
(DRS) were calculated for each subject as the
ratio between percent decline in FEV1 (from the
post-saline value) over the cumulative dose of
Mch (15). Using this procedure we obtained a
continuous index of BHR in the non-responders,
when a FEV1 fall >20% was not obtained.
Data analysis
As the distribution of DRS and PEFv values was
highly skewed, all statistical analyses were per-
formed after natural log transformation (lnDRS
and lnPEFv, respectively) (16). The one-way
anova was used to test diﬀerences between
groups and subgroups. The chi-square analysis
was performed to evaluate diﬀerences in
frequency distributions of variables. The
Mann–Whitney U-test (MWU) was used for
the comparison of non-parametric variables.
The correlation between diﬀerent variables was
tested by simple and multiple linear regression
analysis. A p-value <0.05 was considered
statistically signiﬁcant.
Results
All the selected subjects completed the study.
Rhinitis and control groups were matched for sex
distribution, age, height, and baseline lung func-
tion, as summarized in Table 1. Baseline lung
function was within normal limits in both groups
(17). The median total serum IgE value in
children with allergic rhinitis was signiﬁcantly
higher with respect to the control group
(p ¼ 0.0018, MWU – Table 1).
In the control group, six of 30 (20%) children
had a PD20 within the range of 240–1950 lg
(Mch+ subgroup). Among controls, the IgE
Z-score was not signiﬁcantly diﬀerent between
Mch+andMch) subjects (anova). In the rhinitis
group, the Mch+ children were 31 of 51 (61%),
with a PD20 ranging between 173 and 2010 lg
(Table 1). The frequency distribution analysis
showed a signiﬁcant higher number of Mch+
subjects in the rhinitis group (v2, p ¼ 0.0003), but
the diﬀerence in PD20 between the two subgroups
ofMch+was not signiﬁcant (MWU). Themedian
Table 1. Anthropometric, pulmonary function, and atopy characteristics of the two groups of subjects
Control group (n ¼ 30) Rhinitis group (n ¼ 51) p-Value
Sex (M/F) 18 M; 12 F 29 M; 22 F v2: NS
Age (years) 10.6 € 1.9 10.8 € 2.5 ANOVA: NS
Height (cm) 143.7 € 9.7 144.4 € 13.6 ANOVA NS
Baseline FVC (l) 2.6 € 0.47 2.9 € 0.79 ANOVA NS
Baseline FEV1 (% of
predicted)
106.8 € 10.5 109.9 € 11.5 ANOVA: NS
Baseline FEV1/FVC ratio (absolute %) 90.2 € 5.8 91.3 € 6.7 ANOVA: NS
Total serum IgE, kU/l (median and range) 87 (54–114) 190 (24–1300) MWU: 0.0018
Mch+/Mch) 6/24 31/20 v2: 0.0003
PD20 FEV1 (lg Mch, median and range, for Mch+ subjects only) 445 (240–1950) 695 (173–2010) MWU: NS
DRS (%FEV1 fall/lg Mch, median and range) 0.0025 (0–0.0933) 0.0127 (0.0005–0.1275) MWU: 0.0021
ANOVA, one-way analysis of variance; MWU, Mann–Whitney U-test; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; IgE, immunoglobulin E; DRS,
dose-response slopes; NS, not significant.
Data are expressed as mean € SD unless otherwise indicated.
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DRS was 0.0127 (%FEV1 · lg Mch)1) in rhini-
tics and 0.0025 in controls. The diﬀerence was
statistically signiﬁcant (MWU, p ¼ 0.0021), as
summarized in Table 1.
In the rhinitic children the median total serum
IgE was 422 kU/l (range 25–1300) in Mch+
subgroup, and 173 (24–940) in Mch) subgroup.
The IgE Z-score was signiﬁcantly higher in the
Mch+ subgroup (anova, p < 0.002) as shown
in Table 2. Moreover, a signiﬁcant association
between Mch positivity and persistent rhinitis
was found (v2, p ¼ 0.0013 – Table 3). Con-
versely, age, sex distribution, atopy score
(expressed as number of positive SPT), familial
atopic risk, age at onset of disease, disease
duration, passive smoke exposure, eosinophil
count, and baseline airway function (FVC,
FEV1 % predicted, FEV1/FVC%) did not diﬀer
between Mch+ and Mch) subgroups (Table 2).
In the whole sample (rhinitics and controls),
signiﬁcant inverse linear relationships were found
between lnDRS with age (p ¼ 0.0019, R2 ¼
0.115 – Fig. 1), with height (p ¼ 0.028, R2 ¼
0.061), and with baseline FEV1 (p ¼ 0.045,
R2 ¼ 0.050), while the relationship with FVC
was close to the signiﬁcance level (p ¼ 0.058,
R2 ¼ 0.045). These same relationships showed
an increase in R2 values when evaluated in
Mch+ subjects alone (Table 4).
In rhinitis patients, the median PEFv was
4.89% (range 1.84–11.60) in the Mch+ subgroup
and 4.97% (range 1.75–11.80) in the Mch)
subgroup, the diﬀerence being not signiﬁcant
(Table 2). In the Mch+ subgroup, the lnPEFv
was inversely related to age (p ¼ 0.013, R2 ¼
0.196), to height (p ¼ 0.003, R2 ¼ 0.280), to
FVC (p ¼ 0.002, R2 ¼ 0.290), and to disease
duration (p ¼ 0.015, R2 ¼ 0.187). We also found
a signiﬁcant linear relationship between lnPEFv
and the level of BHR expressed as lnDRS
(p ¼ 0.0021, R2 ¼ 0.282 – Fig. 2).
We performed a multiple linear regression
analysis between lnDRS as dependent variable
and age, height, FVC, Z-score, and lnPEFv as
independent variables. This analysis produced an
increase in R2 value with respect to single linear
regressions: R2 was 0.529, (p ¼ 0.0048) in the
Mch+ subgroup alone.
Table 4. Simple linear regressions between natural log transformation of
dose-response slopes (lnDRS) as dependent variable and some independent
variables in the whole sample (rhinitics and controls) and the methacholine
(Mch+) subjects only. R2 and p-values are shown
Independent variable Whole sample R2 (p) Mch+ R2 (p)
Age 0.115 (0.0019) 0.130 (0.02)
Height 0.061 (0.028) 0.113 (0.04)
Forced vital capacity 0.045 (0.058) 0.145 (0.02)
Z-score 0.0001 (0.94) 0.188 (0.044)
Table 2. Clinical and functional characteristics of the children with allergic
rhinitis (n ¼ 51), for Mch+ and Mch) subgroups
Mch+,
n ¼ 31
(61%)
Mch),
n ¼ 20
(39%) p-Value
Age (years) 10.2 € 2.5 11.6 € 2.3 ANOVA: NS
Baseline FVC (l) 2.80 € 0.78 2.95 € 0.82 ANOVA: NS
Baseline FEV1 (% of
predicted)
110.3 € 10.5 109.4 € 13.2 ANOVA: NS
Baseline FEV1/FVC ratio
(absolute %)
91.4 € 7.5 91.3 € 5.5 ANOVA: NS
IgE Z-score 0.43 € 1.12 )0.52 € 0.59 ANOVA <0.002
PEFv (%, median
and range)
4.89 (1.84–11.6) 4.97 (1.75–11.8) MWU: NS
N of positive skin tests
(median and range)
2 (1–6) 3 (1–10) MWU: NS
Eosinophil count (cell/mm3,
median and range)
241 (90–816) 238 (72–340) MWU: NS
ANOVA, one-way analysis of variance; MWU, Mann–Whitney U-test; Mch,
methacholine; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s;
IgE, immunoglobulin E; NS, not significant
Data are expressed as mean € SD unless otherwise indicated.
Table 3. Contingency table of the distribution of subjects and duration of
rhinitis symptoms in methacholine (Mch+) and Mch) subgroups for rhinitic
subjects (v2, p ¼ 0.0013)
Persistent Intermittent Total
Mch+ 28 3 31
Mch) 10 10 20
Total 38 13 51
0
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D
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Age (yr)
Fig. 1. Linear regression between natural log of metha-
choline (Mch) dose-response slopes (lnDRS, %FEV1 ·
lg Mch)1) and age in the whole sample: R2 ¼ 0.115,
p ¼ 0.0019.
Bronchial responsiveness in atopic children
461
Discussion
The present study conﬁrmed that the prevalence
of BHR is quite high (61%) in non-asthmatic
children with allergic rhinitis and about three-
fold higher than in a control group (20%) of
matched healthy children. BHR, as measured by
Mch test, resulted signiﬁcantly associated with
persistent rhinitis and with higher total serum
IgE levels. Conversely, the spontaneous variab-
ility of airway patency, evaluated by the daily
PEFv, was not diﬀerent between Mch+ and
Mch) children.
We selected a PD20 cut-oﬀ value for positive
BHR of 2250 lg Mch (11.50 lmol), value close
to the level used in a previous study (18). Despite
the large diﬀerence in the number of Mch+
subjects between rhinitis and control groups, we
found similar PD20 values in all Mch+ subjects
(Table 1). The prevalence of Mch test positivity
in the control group is close to that reported in
other studies carried out in asymptomatic
children from open populations showing that
the BHR prevalence is signiﬁcantly higher among
normal children than among adults (19). Indeed,
Koh et al. (5) found a 37% prevalence of BHR,
but this lower prevalence may be explained by
both methodologic diﬀerences relevant to chal-
lenge methods and the selected cut-oﬀ value for
positive BHR. Moreover, the mean total serum
IgE level shown by the population sample in
Koh’s study was lower. As high total serum IgE
level was demonstrated predictive of bronchial
reactivity (20), such diﬀerence may further
account for diﬀerences in BHR prevalence. In
our study, the total serum IgE level, expressed as
Z-score, was signiﬁcantly higher in Mch+ sub-
jects as compared with Mch). Our results further
conﬁrm the well known correlation between
atopy and BHR (21). All subjects with positive
skin tests for seasonal pollens were challenged
out of the pollen season. In fact, children with
perennial allergic rhinitis, the continuous expo-
sure to an oﬀending allergen could induce a
heightened risk of BHR with respect to subjects
with seasonal rhinitis (22). In agreement, we
found that a higher number of subjects with
persistent symptoms was present in the Mch+
subgroup. This suggests that perennial allergen
exposure can maintain a persistent inﬂammation
and sustain BHR, thus supporting the hypothesis
that inﬂammation acts as a link between upper
and lower airways (23).
We found a signiﬁcant inverse relationship
between BHR (expressed as lnDRS), and both
ageandheight, thisﬁndingmaybeattributed to the
eﬀectof lungsize,asexpressedbyageandheight,on
BHR (24). Thus, the lowermean age of population
sample in the present studymay further explain the
higher BHR prevalence we found.
In epidemiological studies, other factors were
related to BHR, such as familial atopic risk,
passive smoke exposure, number of SPTs, and
disease duration. Our study failed in demonstra-
ting these links. This discrepancy may be because
of the homogeneity of our patients, entirely
represented by children with allergic rhinitis.
Furthermore, we found that in non-asthmatic
allergic children the variability of airway patency
is superimposable in children with or without
BHR: only four subjects (two Mch+ and two
Mch)) showed a PEFv higher than 9.26%, value
previously found as 95th percentile limit for
asymptomatic non-asthmatic children (25). In
the present study, in rhinitis patients PEFv was
signiﬁcantly linearly related to DRS, even if the
relationship was stronger among Mch+ subjects
alone and not signiﬁcant among Mch). It is
noteworthy that despite this relationship, the
spontaneous airway reactivity, expressed by
PEFv, was not distinguishable among Mch+
and Mch) subjects. From a clinical point of view
these results suggest that in non-asthmatic chil-
dren the presence of BHR does not imply an
abnormal behavior of airways, as found in
asthmatics (2). In rhinitic non-asthmatic chil-
dren, a positive Mch test is not deﬁnitely
associated with abnormal spontaneous diurnal
changes in airway patency.
In conclusion, in a selected sample of children
with allergic rhinitis alone we found a very high
prevalence of asymptomatic BHR. This was
associated with persistent rhinitis and higher
0
0.02
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0.08
0.1
0.12
0.14
Ln
D
R
S
0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2 2.2 2.4 2.6
LnPEFv
Fig. 2. Linear regression between natural log of mean daily
peak expiratory ﬂow (PEF) variability (lnPEFv, %) and
natural log of methacholine (Mch) dose-response slopes
(lnDRS, %FEV1 · lg Mch)1) in the Mch+ rhinitis sub-
group alone: R2 ¼ 0.283, p ¼ 0.0021.
Cuttitta et al.
462
total serum IgE levels. Nevertheless, the sponta-
neous changes in airway patency, as expressed by
diurnal variability of peak expiratory ﬂow, were
within normal limits both in responder and non-
responder children.
References
1. Hopp RJ, Townley RG, Biven RE, Bewtra AK, Nair
NM. The presence of airway reactivity before the
development of asthma. Am Rev Respir Dis 1990: 141:
2–8.
2. Ryan G, Latimer KM, Dolovich J, Hargreave FE.
Bronchial responsiveness to histamine: relationship to
diurnal variation of peak ﬂow rate, improvement after
bronchodilator, and airway calibre. Thorax 1982: 37:
423–9.
3. Hopp RJ, Bewtra A, Nair NM, Townley RG. The
eﬀect of age on methacholine response. J Allergy Clin
Immunol 1985: 76: 609–13.
4. Ramsdale EH, Morris MM, Roberts RS, Hargreave
FE. Asymptomatic bronchial hyperresponsiveness in
rhinitis. J Allergy Clin Immunol 1985: 75: 573–7.
5. Koh YY, Lee MH, Kim CK, et al. A familial predis-
position in bronchial hyperresponsiveness among
patients with allergic rhinitis. J Allergy Clin Immunol
1998: 702: 921–6.
6. Grembiale RD, Camporota L, Naty S, Tranfa CM,
Djukanovic R, Marsico SA. Eﬀects of speciﬁc immu-
notherapy in allergic rhinitic individuals with bronchial
hyperresponsiveness. Am J Respir Crit Care Med 2000:
162: 2048–52.
7. The International Rhinitis Management Working
Group. International Consensus Report on the Diag-
nosis and Management of Rhinitis. Allergy1994: 49
(Suppl 19): 1–34.
8. Croner S, Kjellman NI. Development of atopic dis-
ease in relation to family history and cord blood IgE
levels: eleven-years follow-up in 1654 children. Pediatr
Allergy Immunol 1990: 1: 14–20.
9. Bousquet J, Van Cauwenberge P, Khaltaev N. Aria
Workshop Group. World Health Organization. Allergic
rhinitis and its impact on asthma. J Allergy Clin
Immunol 2001: 108: S147–334.
10. Dreborg S, Frew A. Position paper: allergen stan-
dardization and skin tests. Allergy 1993: 48(suppl 14):
57–62.
11. Burrows B, Martinez FD, Halonen M, Barbee RA,
Cline MG. Association of asthma with serum IgE levels
and to skin-test rectivity to allergens. N Engl J Med
1989: 320: 271–7.
12. Axen R, Drevin H, Kober A, Yman L. A new labor-
atory diagnostic system applied to allergy testing. N
Engl Reg Allergy Proc 1988: 9: 503–8.
13. Higgins BG, Britton JR, Chinn S, et al. The dis-
tribution of peak expiratory ﬂow variability in a
population sample. Am Rev Respir Dis 1989: 140:
1368–72.
14. Sterk PJ, Fabbri LM, Quanjer PhH, et al. Airway
responsiveness. Standardized challenge testing with
pharmacological, physical and sensitizing stimuli in
adults. Eur Respir J 1993: 6(Suppl 16): 53–83.
15. O’Connor G, Sparrow D, Taylor D, Segal M, Weiss
S. Analysis of dose-response curves to methacholine.
Am Rev Respir Dis 1987: 36: 1412–7.
16. Paoletti P, Carrozzi L, Viegi G, et al. Distribution of
bronchial responsiveness in a general population: eﬀect
of sex, age, smoking and level of pulmonary function.
Am J Respir Crit Care Med 1995: 151: 1770–7.
17. Polgar G, Promadhat V. Pulmonary function testing
in children: techniques and standards. Philadelphia,
London, Toronto: WB Saunders Co, 1971.
18. Josephs LK, Gregg I, Mullee MA, Holgate ST.
Nonspeciﬁc bronchial rectivity and its relationship to
the clinical expression of asthma. Am Rev Respir Dis
1989: 140: 350–7.
19. Weiss ST, Tager IB, Weiss JW, Munoz A, Speizer FE,
Ingram RH. Airway responsiveness in a population
sample of adults and children. Am Rev Respir Dis 1984:
129: 898–902.
20. Sears MR, Burrows B, Flannery EM, Herbison GP,
Hewitt CJ, Holdaway MD. Relation between airway
responsiveness and serum IgE in children with asthma
and in apparently normal children. N Engl J Med 1991:
325: 1067–71.
21. Crockcroft DW, Murdock KY, Berscheid BA.
Relationship between atopy and bronchial responsive-
ness to histamine in a random population. Ann Allergy
1984: 53: 26–9.
22. Verdiani P, Di Carlo S, Baronti A. Diﬀerent prevalence
and degree of nonspeciﬁc bronchial hyperreactivity
between seasonal and perennial rhinitis. J Allergy Clin
Immunol 1990: 86: 576–82.
23. Passalacqua G, Canonica GW. Impact of rhinitis on
airway inﬂammation: biological and therapeutic impli-
cations. Respir Res 2001: 2: 320–3.
24. Peat JK, Salome CM, Xuan W. On adjusting meas-
urements of airway responsiveness for lung size and
airway caliber. Am J Respir Crit Care Med 1996: 154:
870–5.
25. Siersted HC, Hansen HS, Hansen N-CG, Hylde-
brandt N, Mostgaard G, Oxhoj H. Evaluation of
peak expiratory ﬂow variability in an adolescent popu-
lation sample. Am J Respir Crit Care Med 1994: 149:
598–603.
Bronchial responsiveness in atopic children
463
